Over the past two years, for instance, he has published studies maintaining the Chantix anti-smoking pill is unsuitable for first-line use (read here and here) and a meta-analysis indicating the mist form of the Spiriva inhaler that is used to treat chronic obstructive pulmonary disease had a 52 percent increase in mortality risk compared with a placebo ( see this).

FORBES: The Confusion Over A Pair Of Diabetes Drugs And Pancreatitis

"It's concerning to us, because we're worried that patients who really aren't experts and read this casually could interpret that the ACC endorse this as a first-line therapy, " says Weaver.

FORBES: Magazine Article